|
Gene: FOLR1 |
Gene summary for FOLR1 |
Gene summary. |
Gene information | Species | Human | Gene symbol | FOLR1 | Gene ID | 2348 |
Gene name | folate receptor alpha | |
Gene Alias | FBP | |
Cytomap | 11q13.4 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | A0A024R5H1 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
2348 | FOLR1 | CA_HPV_1 | Human | Cervix | CC | 8.81e-06 | -1.93e-01 | 0.0264 |
2348 | FOLR1 | CA_HPV_2 | Human | Cervix | CC | 9.91e-06 | -1.88e-01 | 0.0391 |
2348 | FOLR1 | CA_HPV_3 | Human | Cervix | CC | 3.43e-03 | -1.83e-01 | 0.0414 |
2348 | FOLR1 | N_HPV_1 | Human | Cervix | N_HPV | 2.92e-04 | -1.80e-01 | 0.0079 |
2348 | FOLR1 | CCII_1 | Human | Cervix | CC | 2.78e-02 | -1.93e-01 | 0.3249 |
2348 | FOLR1 | Tumor | Human | Cervix | CC | 1.12e-04 | -1.82e-01 | 0.1241 |
2348 | FOLR1 | sample3 | Human | Cervix | CC | 2.55e-03 | -1.92e-01 | 0.1387 |
2348 | FOLR1 | H2 | Human | Cervix | HSIL_HPV | 2.24e-03 | 3.02e-01 | 0.0632 |
2348 | FOLR1 | L1 | Human | Cervix | CC | 9.03e-03 | -1.93e-01 | 0.0802 |
2348 | FOLR1 | T1 | Human | Cervix | CC | 3.54e-02 | -1.74e-01 | 0.0918 |
2348 | FOLR1 | T2 | Human | Cervix | CC | 3.97e-14 | 9.06e-01 | 0.0709 |
2348 | FOLR1 | T3 | Human | Cervix | CC | 4.13e-06 | -1.93e-01 | 0.1389 |
2348 | FOLR1 | EEC-subject1 | Human | Endometrium | EEC | 1.55e-02 | -1.05e-01 | -0.2682 |
2348 | FOLR1 | EEC-subject3 | Human | Endometrium | EEC | 3.99e-06 | -1.58e-01 | -0.2525 |
2348 | FOLR1 | GSM6177620_NYU_UCEC1_lib1_lib1 | Human | Endometrium | EEC | 1.11e-04 | 4.16e-01 | -0.1869 |
2348 | FOLR1 | GSM6177620_NYU_UCEC1_lib3_lib3 | Human | Endometrium | EEC | 2.45e-04 | 3.46e-01 | -0.1883 |
2348 | FOLR1 | GSM6177621_NYU_UCEC2_lib1_lib1 | Human | Endometrium | EEC | 3.86e-04 | -1.63e-01 | -0.1934 |
2348 | FOLR1 | GSM6177622_NYU_UCEC3_lib1_lib1 | Human | Endometrium | EEC | 1.10e-09 | 4.33e-01 | -0.1917 |
2348 | FOLR1 | GSM6177622_NYU_UCEC3_lib2_lib2 | Human | Endometrium | EEC | 8.20e-14 | 5.53e-01 | -0.1916 |
2348 | FOLR1 | GSM6177623_NYU_UCEC3_Vis | Human | Endometrium | EEC | 1.04e-11 | 5.40e-01 | -0.1269 |
Page: 1 2 3 4 5 6 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000657522 | Thyroid | ATC | cellular modified amino acid metabolic process | 82/6293 | 188/18723 | 2.60e-03 | 1.20e-02 | 82 |
GO:00613072 | Thyroid | ATC | cardiac neural crest cell differentiation involved in heart development | 9/6293 | 12/18723 | 4.10e-03 | 1.75e-02 | 9 |
GO:00613082 | Thyroid | ATC | cardiac neural crest cell development involved in heart development | 9/6293 | 12/18723 | 4.10e-03 | 1.75e-02 | 9 |
GO:0003151 | Thyroid | ATC | outflow tract morphogenesis | 36/6293 | 74/18723 | 5.19e-03 | 2.12e-02 | 36 |
GO:00488441 | Thyroid | ATC | artery morphogenesis | 36/6293 | 74/18723 | 5.19e-03 | 2.12e-02 | 36 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0414418 | Cervix | CC | Endocytosis | 64/1267 | 251/8465 | 6.97e-06 | 6.10e-05 | 3.61e-05 | 64 |
hsa0414419 | Cervix | CC | Endocytosis | 64/1267 | 251/8465 | 6.97e-06 | 6.10e-05 | 3.61e-05 | 64 |
hsa0414424 | Endometrium | EEC | Endocytosis | 57/1237 | 251/8465 | 3.34e-04 | 2.82e-03 | 2.10e-03 | 57 |
hsa0414434 | Endometrium | EEC | Endocytosis | 57/1237 | 251/8465 | 3.34e-04 | 2.82e-03 | 2.10e-03 | 57 |
hsa0414429 | Esophagus | HGIN | Endocytosis | 76/1383 | 251/8465 | 1.74e-08 | 3.34e-07 | 2.65e-07 | 76 |
hsa04144113 | Esophagus | HGIN | Endocytosis | 76/1383 | 251/8465 | 1.74e-08 | 3.34e-07 | 2.65e-07 | 76 |
hsa04144210 | Esophagus | ESCC | Endocytosis | 186/4205 | 251/8465 | 9.74e-16 | 4.66e-14 | 2.39e-14 | 186 |
hsa015232 | Esophagus | ESCC | Antifolate resistance | 22/4205 | 30/8465 | 7.23e-03 | 1.76e-02 | 8.99e-03 | 22 |
hsa0414437 | Esophagus | ESCC | Endocytosis | 186/4205 | 251/8465 | 9.74e-16 | 4.66e-14 | 2.39e-14 | 186 |
hsa0152311 | Esophagus | ESCC | Antifolate resistance | 22/4205 | 30/8465 | 7.23e-03 | 1.76e-02 | 8.99e-03 | 22 |
hsa0414422 | Liver | HCC | Endocytosis | 178/4020 | 251/8465 | 2.03e-14 | 5.22e-13 | 2.91e-13 | 178 |
hsa01523 | Liver | HCC | Antifolate resistance | 21/4020 | 30/8465 | 1.06e-02 | 2.71e-02 | 1.51e-02 | 21 |
hsa0414432 | Liver | HCC | Endocytosis | 178/4020 | 251/8465 | 2.03e-14 | 5.22e-13 | 2.91e-13 | 178 |
hsa015231 | Liver | HCC | Antifolate resistance | 21/4020 | 30/8465 | 1.06e-02 | 2.71e-02 | 1.51e-02 | 21 |
hsa0414414 | Lung | IAC | Endocytosis | 51/1053 | 251/8465 | 2.25e-04 | 2.54e-03 | 1.68e-03 | 51 |
hsa0414415 | Lung | IAC | Endocytosis | 51/1053 | 251/8465 | 2.25e-04 | 2.54e-03 | 1.68e-03 | 51 |
hsa0414423 | Lung | AIS | Endocytosis | 52/961 | 251/8465 | 9.74e-06 | 3.04e-04 | 1.95e-04 | 52 |
hsa0414433 | Lung | AIS | Endocytosis | 52/961 | 251/8465 | 9.74e-06 | 3.04e-04 | 1.95e-04 | 52 |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FOLR1 | SNV | Missense_Mutation | novel | c.699G>C | p.Met233Ile | p.M233I | P15328 | protein_coding | tolerated(0.15) | benign(0.015) | TCGA-A7-A26H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | PD |
FOLR1 | SNV | Missense_Mutation | c.668A>T | p.Glu223Val | p.E223V | P15328 | protein_coding | tolerated(0.51) | benign(0.145) | TCGA-D8-A1JP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | |
FOLR1 | insertion | In_Frame_Ins | novel | c.294_295insGCACAATCTCAGCTCACTGCAACCTCCACCTCCCAGGTT | p.Arg98_His99insAlaGlnSerGlnLeuThrAlaThrSerThrSerGlnVal | p.R98_H99insAQSQLTATSTSQV | P15328 | protein_coding | TCGA-BH-A0E2-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | ||
FOLR1 | insertion | In_Frame_Ins | novel | c.262_263insTCATGCCACTCAGATGTTCCA | p.His88delinsLeuMetProLeuArgCysSerAsn | p.H88delinsLMPLRCSN | P15328 | protein_coding | TCGA-C8-A3M8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | CR | ||
FOLR1 | SNV | Missense_Mutation | rs747612073 | c.633N>C | p.Gln211His | p.Q211H | P15328 | protein_coding | deleterious(0.02) | probably_damaging(1) | TCGA-EK-A2PG-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
FOLR1 | SNV | Missense_Mutation | c.248G>T | p.Arg83Ile | p.R83I | P15328 | protein_coding | deleterious(0) | benign(0.435) | TCGA-A6-6141-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | 5-fu | SD | |
FOLR1 | SNV | Missense_Mutation | rs752503322 | c.373C>T | p.Arg125Cys | p.R125C | P15328 | protein_coding | deleterious(0.01) | probably_damaging(0.953) | TCGA-AA-3833-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
FOLR1 | SNV | Missense_Mutation | c.548C>A | p.Pro183His | p.P183H | P15328 | protein_coding | deleterious(0.03) | probably_damaging(0.996) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
FOLR1 | SNV | Missense_Mutation | novel | c.43N>C | p.Trp15Arg | p.W15R | P15328 | protein_coding | deleterious(0.01) | benign(0.11) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
FOLR1 | SNV | Missense_Mutation | c.706G>A | p.Ala236Thr | p.A236T | P15328 | protein_coding | tolerated(0.12) | benign(0.005) | TCGA-G4-6586-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2348 | FOLR1 | CELL SURFACE, TRANSPORTER, DRUGGABLE GENOME | FARLETUZUMAB | FARLETUZUMAB | ||
2348 | FOLR1 | CELL SURFACE, TRANSPORTER, DRUGGABLE GENOME | ANTIESTROGENS | 12782587 | ||
2348 | FOLR1 | CELL SURFACE, TRANSPORTER, DRUGGABLE GENOME | EC0489 | |||
2348 | FOLR1 | CELL SURFACE, TRANSPORTER, DRUGGABLE GENOME | inhibitor | CHEMBL1743016 | FARLETUZUMAB | |
2348 | FOLR1 | CELL SURFACE, TRANSPORTER, DRUGGABLE GENOME | FolateImmune | |||
2348 | FOLR1 | CELL SURFACE, TRANSPORTER, DRUGGABLE GENOME | IMGN-853 | MIRVETUXIMAB SORAVTANSINE | ||
2348 | FOLR1 | CELL SURFACE, TRANSPORTER, DRUGGABLE GENOME | Mirvetuximab soravtansine | |||
2348 | FOLR1 | CELL SURFACE, TRANSPORTER, DRUGGABLE GENOME | Farletuzumab | FARLETUZUMAB | ||
2348 | FOLR1 | CELL SURFACE, TRANSPORTER, DRUGGABLE GENOME | Tetrahydrofolic acid | |||
2348 | FOLR1 | CELL SURFACE, TRANSPORTER, DRUGGABLE GENOME | EC-145 | VINTAFOLIDE | 23242435 |
Page: 1 2 3 |